STOCKS | Novartis, Boston Scientific Fall as Intel Rises on Price-Hike Report

Novartis shares fell after a treatment for a rare muscle-wasting disease failed a late-stage study, its third clinical-trial setback in a week, according to Bloomberg. Boston Scientific said fallout from a cybersecurity incident has affected its ability to ship products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year. Intel rose on a report that the company could raise computer chip prices next month.